nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA1—forebrain—attention deficit hyperactivity disorder	0.0464	0.0803	CbGeAlD
Lithium—GRIA3—forebrain—attention deficit hyperactivity disorder	0.0395	0.0683	CbGeAlD
Lithium—IMPA1—cardiovascular system—attention deficit hyperactivity disorder	0.0392	0.0679	CbGeAlD
Lithium—GSK3B—forebrain—attention deficit hyperactivity disorder	0.0342	0.0592	CbGeAlD
Lithium—GSK3A—forebrain—attention deficit hyperactivity disorder	0.0297	0.0514	CbGeAlD
Lithium—GSK3B—cardiovascular system—attention deficit hyperactivity disorder	0.0289	0.05	CbGeAlD
Lithium—GRIA3—midbrain—attention deficit hyperactivity disorder	0.0261	0.0451	CbGeAlD
Lithium—IMPA1—nervous system—attention deficit hyperactivity disorder	0.0252	0.0436	CbGeAlD
Lithium—GSK3A—cardiovascular system—attention deficit hyperactivity disorder	0.0251	0.0435	CbGeAlD
Lithium—IMPA1—central nervous system—attention deficit hyperactivity disorder	0.0243	0.042	CbGeAlD
Lithium—GRIA3—Hypothetical Network for Drug Addiction—DRD1—attention deficit hyperactivity disorder	0.0231	0.0547	CbGpPWpGaD
Lithium—GRIA3—Hypothetical Network for Drug Addiction—DRD4—attention deficit hyperactivity disorder	0.0217	0.0514	CbGpPWpGaD
Lithium—GRIA3—nervous system—attention deficit hyperactivity disorder	0.0214	0.0371	CbGeAlD
Lithium—GRIA3—central nervous system—attention deficit hyperactivity disorder	0.0206	0.0357	CbGeAlD
Lithium—GRIA3—Hypothetical Network for Drug Addiction—DRD2—attention deficit hyperactivity disorder	0.0202	0.0479	CbGpPWpGaD
Lithium—GRIA3—cerebellum—attention deficit hyperactivity disorder	0.0202	0.0349	CbGeAlD
Lithium—GSK3A—midbrain—attention deficit hyperactivity disorder	0.0196	0.034	CbGeAlD
Lithium—IMPA1—brain—attention deficit hyperactivity disorder	0.0193	0.0333	CbGeAlD
Lithium—GSK3B—nervous system—attention deficit hyperactivity disorder	0.0185	0.0321	CbGeAlD
Lithium—GSK3B—central nervous system—attention deficit hyperactivity disorder	0.0179	0.0309	CbGeAlD
Lithium—GSK3B—cerebellum—attention deficit hyperactivity disorder	0.0175	0.0302	CbGeAlD
Lithium—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.0173	0.041	CbGpPWpGaD
Lithium—GRIA3—brain—attention deficit hyperactivity disorder	0.0164	0.0283	CbGeAlD
Lithium—GSK3A—nervous system—attention deficit hyperactivity disorder	0.0161	0.0279	CbGeAlD
Lithium—GSK3A—central nervous system—attention deficit hyperactivity disorder	0.0155	0.0269	CbGeAlD
Lithium—GSK3A—cerebellum—attention deficit hyperactivity disorder	0.0152	0.0263	CbGeAlD
Lithium—IMPA2—brain—attention deficit hyperactivity disorder	0.0144	0.025	CbGeAlD
Lithium—GSK3B—brain—attention deficit hyperactivity disorder	0.0142	0.0245	CbGeAlD
Lithium—GRIA3—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.013	0.0308	CbGpPWpGaD
Lithium—GSK3A—brain—attention deficit hyperactivity disorder	0.0123	0.0213	CbGeAlD
Lithium—GSK3A—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.0117	0.0277	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—STUB1—attention deficit hyperactivity disorder	0.0114	0.0269	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00998	0.0236	CbGpPWpGaD
Lithium—GSK3B—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00996	0.0236	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00949	0.0225	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.00864	0.0205	CbGpPWpGaD
Lithium—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.00763	0.0181	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00701	0.0166	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.00679	0.0161	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00667	0.0158	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00573	0.0136	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00533	0.0126	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00511	0.0121	CbGpPWpGaD
Lithium—GRIA3—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00503	0.0119	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.005	0.0118	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00475	0.0112	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00457	0.0108	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00439	0.0104	CbGpPWpGaD
Lithium—GSK3A—FOXM1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00433	0.0102	CbGpPWpGaD
Lithium—IMPA1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00413	0.00977	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00408	0.00967	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00404	0.00956	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00401	0.00949	CbGpPWpGaD
Lithium—IMPA2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00398	0.00942	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00369	0.00874	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00364	0.00862	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00356	0.00844	CbGpPWpGaD
Lithium—IMPA1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00355	0.0084	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.00352	0.00832	CbGpPWpGaD
Lithium—GSK3B—Cellular response to heat stress—EP300—attention deficit hyperactivity disorder	0.00346	0.0082	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00341	0.00806	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00337	0.00799	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00331	0.00785	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—COMT—attention deficit hyperactivity disorder	0.0031	0.00733	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00307	0.00727	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00288	0.00681	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.00281	0.00665	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.00281	0.00665	CbGpPWpGaD
Lithium—IMPA2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00275	0.0065	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00275	0.0065	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.00272	0.00644	CbGpPWpGaD
Lithium—IMPA2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.0027	0.0064	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00267	0.00631	CbGpPWpGaD
Lithium—GSK3B—Regulation of Androgen receptor activity—EP300—attention deficit hyperactivity disorder	0.00265	0.00628	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.00264	0.00626	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00263	0.00623	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00262	0.00619	CbGpPWpGaD
Lithium—GSK3B—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—attention deficit hyperactivity disorder	0.00261	0.00619	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00251	0.00595	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.00246	0.00583	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00245	0.0058	CbGpPWpGaD
Lithium—IMPA1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00245	0.0058	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00245	0.0058	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—EP300—attention deficit hyperactivity disorder	0.00244	0.00577	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00243	0.00575	CbGpPWpGaD
Lithium—IMPA1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00241	0.0057	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.0024	0.00568	CbGpPWpGaD
Lithium—GSK3B—Notch Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00237	0.00561	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00224	0.0053	CbGpPWpGaD
Lithium—IMPA2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.0022	0.0052	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.0022	0.0052	CbGpPWpGaD
Lithium—IMPA2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00209	0.00495	CbGpPWpGaD
Lithium—GSK3A—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00208	0.00491	CbGpPWpGaD
Lithium—GSK3A—Immune System—STUB1—attention deficit hyperactivity disorder	0.00201	0.00476	CbGpPWpGaD
Lithium—IMPA1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00196	0.00463	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00193	0.00458	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—EP300—attention deficit hyperactivity disorder	0.00187	0.00443	CbGpPWpGaD
Lithium—IMPA1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00186	0.00441	CbGpPWpGaD
Lithium—GSK3A—Disease—STUB1—attention deficit hyperactivity disorder	0.00186	0.00439	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.00175	0.00415	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00171	0.00405	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00167	0.00394	CbGpPWpGaD
Lithium—IMPA2—Metabolism—COMT—attention deficit hyperactivity disorder	0.00166	0.00394	CbGpPWpGaD
Lithium—IMPA2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00165	0.00391	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.00157	0.00372	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—EP300—attention deficit hyperactivity disorder	0.00157	0.00372	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00157	0.00371	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00155	0.00368	CbGpPWpGaD
Lithium—GSK3B—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00153	0.00363	CbGpPWpGaD
Lithium—GSK3A—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00152	0.00361	CbGpPWpGaD
Lithium—GSK3B—Immune System—STUB1—attention deficit hyperactivity disorder	0.00149	0.00352	CbGpPWpGaD
Lithium—IMPA1—Metabolism—COMT—attention deficit hyperactivity disorder	0.00148	0.00351	CbGpPWpGaD
Lithium—IMPA1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00147	0.00349	CbGpPWpGaD
Lithium—GSK3B—Disease—STUB1—attention deficit hyperactivity disorder	0.00137	0.00325	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.0013	0.00308	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00129	0.00305	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00123	0.00291	CbGpPWpGaD
Lithium—GSK3B—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00113	0.00267	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00264	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00109	0.00259	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00107	0.00254	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000961	0.00227	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.000914	0.00216	CbGpPWpGaD
Lithium—GSK3A—Disease—SNAP25—attention deficit hyperactivity disorder	0.00088	0.00208	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—EP300—attention deficit hyperactivity disorder	0.000856	0.00203	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—EP300—attention deficit hyperactivity disorder	0.000829	0.00196	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000825	0.00195	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000809	0.00191	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000793	0.00188	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—EP300—attention deficit hyperactivity disorder	0.00077	0.00182	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000758	0.0018	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000735	0.00174	CbGpPWpGaD
Lithium—IMPA2—Metabolism—EP300—attention deficit hyperactivity disorder	0.000714	0.00169	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000663	0.00157	CbGpPWpGaD
Lithium—GSK3B—Disease—SNAP25—attention deficit hyperactivity disorder	0.00065	0.00154	CbGpPWpGaD
Lithium—IMPA1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000636	0.00151	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—EP300—attention deficit hyperactivity disorder	0.000635	0.0015	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000616	0.00146	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000597	0.00141	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000587	0.00139	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000579	0.00137	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00056	0.00133	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00054	0.00128	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000532	0.00126	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00049	0.00116	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000455	0.00108	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000445	0.00105	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000441	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000434	0.00103	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000428	0.00101	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000399	0.000944	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000393	0.00093	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000378	0.000895	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—attention deficit hyperactivity disorder	0.00031	0.000733	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—attention deficit hyperactivity disorder	0.000286	0.000677	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000279	0.000661	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—attention deficit hyperactivity disorder	0.000229	0.000542	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—attention deficit hyperactivity disorder	0.000211	0.0005	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.0002	0.000474	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000148	0.00035	CbGpPWpGaD
